Last reviewed · How we verify
5FU-Calcipotriol
At a glance
| Generic name | 5FU-Calcipotriol |
|---|---|
| Sponsor | Maastricht University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart (NA)
- 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer (PHASE2, PHASE3)
- A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses (PHASE3)
- Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients (PHASE2)
- Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC (PHASE1)
- Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis (PHASE4)
- Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 5FU-Calcipotriol CI brief — competitive landscape report
- 5FU-Calcipotriol updates RSS · CI watch RSS
- Maastricht University Medical Center portfolio CI